Results 81 to 90 of about 5,338,575 (282)

Visual exploration in Parkinson's disease and Parkinson's disease dementia [PDF]

, 2013
Parkinson's disease, typically thought of as a movement disorder, is increasingly recognized as causing cognitive impairment and dementia. Eye movement abnormalities are also described, including impairment of rapid eye movements (saccades) and the ...
Archibald, Neil K., Hutton, Sam B., Burn, David J., Mosimann, Urs P., Clarke, Michael P.   +4 more
core   +2 more sources

Handgrip Strength and Anthropometry in Parkinson's Disease at Diagnosis

, 2022
Objectives. To investigate how age, malnutrition, and the level of plasma cortisol and phosphate in patients with Parkinson's disease (PD) at time of diagnosis are associated with body composition and handgrip strength in males and females compared to ...
Lennart Bäckman, Bäckman, Lennart, Lena Håglin, Edström, Mona, Mona Edström, Birgitta Törnkvist, Håglin, Lena, Törnkvist, Birgitta, Sofia Håglin, Håglin, Sofia, Edström, Mona,, Håglin, Lena,, Bäckman, Lennart,, Törnkvist, Birgitta,, Håglin, Sofia,   +14 more
core   +1 more source

Basal ganglia oscillations as biomarkers for targeting circuit dysfunction in Parkinson's disease [PDF]

, 2020
Oscillations are a naturally occurring phenomenon in highly interconnected dynamical systems. However, it is thought that excessive synchronized oscillations in brain circuits can be detrimental for many brain functions by disrupting neuronal information
Wolf-Julian Neumann, Andrea A. Kühn, Kuehn, Andrea A., Fuentes, Romulo, Petersson, Per, Petersson, Per,, Kühn, Andrea A., Per Petersson, Romulo Fuentes, Neumann, Wolf Julian, Neumann, Wolf-Julian, Kühn, Andrea A.,, Neumann, Wolf Julian,, Fuentes, Romulo,, Lund University.   +14 more
core   +1 more source

Neurochemical Endpoints to Inform Early‐Stage Trials of Spinocerebellar Ataxia 2 and 3 in a Multisite Setting

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neurochemical levels measured by brain MR spectroscopy (MRS) have been proposed as endpoints for clinical trials in early‐stage spinocerebellar ataxia (SCA) trials. We tested their trial‐readiness by quantifying neurochemicals in three affected brain regions in early‐stage cohorts of SCA2 and SCA3, examining their reproducibility in ...
James M. Joers, Yaqiao Wei, Dinesh K. Deelchand, Adam Berrington, Young Woo Park, Guita Banan, Michal Povazan, Jens T. Rosenberg, André J. W. van der Kouwe, Tetsuo Ashizawa, Khalaf O. Bushara, Chiadi U. Onyike, Sub H. Subramony, Jeremy D. Schmahmann, Brian J. Soher, Peter B. Barker, Thomas H. Mareci, Eva‐Maria Ratai, Lynn E. Eberly, Gülin Öz   +19 more
wiley   +1 more source

Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease

Parkinson's Disease, 2010
Clinical trials have demonstrated positive proof of efficacy of dual metabotropic glutamate receptor 2/3 (mGluR2/3) agonists in both anxiety and schizophrenia.
Hugh Chan, Helen Paur, Anthony C. Vernon, Virginia Zabarsky, Krishna P. Datla, Martin J. Croucher, David T. Dexter   +6 more
doaj   +1 more source

Neuroimaging in pre-motor Parkinson's disease

NeuroImage: Clinical, 2017
The process of neurodegeneration in Parkinson's disease begins long before the onset of clinical motor symptoms, resulting in substantial cell loss by the time a diagnosis can be made. The period between the onset of neurodegeneration and the development
Thomas R. Barber, Johannes C. Klein, Clare E. Mackay, Michele T.M. Hu   +3 more
doaj   +1 more source

Models of probabilistic category learning in Parkinson's disease: Strategy use and the effects of L-dopa [PDF]

, 2010
Probabilistic category learning (PCL) has become an increasingly popular paradigm to study the brain bases of learning and memory. It has been argued that PCL relies on procedural habit learning, which is impaired in Parkinson's disease (PD). However, as
Lagnado, DA, Shanks, DR, Jahanshahi, M, Speekenbrink, M, Wilkinson, L   +4 more
core  

Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016? [Elektronisk resurs]

, 2016
Recent news of an impending clinical cell transplantation trial in Parkinson's disease using parthenogenetic stem cells as a source of donor tissue have raised hopes in the patient community and sparked discussion in the research community.
Brundin, Patrik,, Barker, Roger A,, Björklund, Anders,, Parmar, Malin,, Kirkeby, Agnete,, Lund University., Thompson, Lachlan,   +6 more
core   +1 more source

The effectiveness of traditional methods and altered auditory feedback in improving speech rate and intelligibility in speakers with Parkinson's disease [PDF]

, 2010
Communication problems are a frequent symptom for people with Parkinson's disease (PD) which can have a significant impact on their quality-of-life. Deciding on the right management approach can be problematic though, as, with the exception of LSVT (R ...
Kröger, Bernd J., Bernd Kröger, Lowit, Anja, Anja Lowit, Howell, Peter, Corinne Dobinson, Claire Timmins, Dobinson, Corinne, Peter Howell, Timmins, Claire, Kröger, Bernd   +10 more
core   +1 more source

Characterizing Cutaneous α‐Synuclein Deposition and Seeding Activity in Parkinson's Disease Subtypes

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cutaneous phosphorylated α‐synuclein (p‐syn) and α‐synuclein seeding activity are promising biomarkers for Parkinson's disease (PD), but their clinical value remains uncertain due to disease heterogeneity. This study evaluates these two biomarkers in PD patients to inform phenotype‐specific diagnosis and disease severity assessment ...
Yuting Jin, Tianyuan Yang, Minglei Liu, Haiyang Luo, Jing Yuan, Ke Zhang, Xinsheng Han, Jing Yang, Yuming Xu   +8 more
wiley   +1 more source